- Home
- GENI vs GLUE Comparison
GENI vs GLUE Comparison
Compare GENI & GLUE Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | GENI | GLUE |
|---|---|---|
| Founded | 2016 | 2019 |
| Country | United Kingdom | United States |
| Employees | N/A | N/A |
| Industry | Services-Misc. Amusement & Recreation | Biotechnology: Pharmaceutical Preparations |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 1.6B | 1.7B |
| IPO Year | 2021 | 2021 |
Fundamental Metrics
Financial Performance| Metric | GENI | GLUE |
|---|---|---|
| Price | $6.18 | $18.50 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 16 | 3 |
| Target Price | $12.75 | ★ $32.00 |
| AVG Volume (30 Days) | ★ 6.4M | 881.9K |
| Earning Date | 05-07-2026 | 05-08-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | N/A | N/A |
| Revenue | N/A | ★ $123,672,000.00 |
| Revenue This Year | $24.00 | N/A |
| Revenue Next Year | $20.12 | $2.45 |
| P/E Ratio | ★ N/A | $72.42 |
| Revenue Growth | N/A | ★ 63.54 |
| 52 Week Low | $3.83 | $4.12 |
| 52 Week High | $13.73 | $25.77 |
Technical Indicators
Market Signals| Indicator | GENI | GLUE |
|---|---|---|
| Relative Strength Index (RSI) | 52.98 | 51.69 |
| Support Level | $5.68 | $17.07 |
| Resistance Level | $6.75 | $18.66 |
| Average True Range (ATR) | 0.50 | 1.18 |
| MACD | -0.00 | 0.06 |
| Stochastic Oscillator | 32.63 | 51.53 |
Price Performance
Historical ComparisonAbout GENI Genius Sports Limited
Genius Sports Ltd is a B2B provider of scalable, technology-led products and services to the sports, sports betting, and sports media industries. Its services are organized into three key product areas: Sports Technology and Services; Betting Technology, Content, and Services; and Media Technology, Content, and Services. All of its products are powered by proprietary technology and robust data infrastructure. It generates maximum revenue from the Betting Technology, Content, and Services division. Geographically, the company derives a majority of its revenue from America.
About GLUE Monte Rosa Therapeutics Inc.
Monte Rosa Therapeutics Inc is a clinical-stage biotechnology company that specializes in developing molecular glue degraders (MGDs), a class of small molecule drugs that leverage the body's natural protein destruction mechanisms to selectively degrade therapeutically-relevant proteins. Utilizing the QuEEN platform, the company employ artificial intelligence and proprietary experimental tools to identify target proteins for degradation by MGDs. The company has three programs in clinical development: MRT-6160, a VAV1-directed MGD for immune-mediated diseases; MRT-8102, a NEK7-directed MGD for inflammatory diseases driven by IL-6, and the NLRP3 inflammasome; and MRT-2359, a GSPT1-directed MGD for metastatic castration resistant prostate cancer (mCRPC).